Incyte Genomics financials
$123.20−1.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B | $1.14B | $1.04B | $880.9M | $1.01B | $919.0M |
| Gross profit | $1.57B | $1.17B | $1.39B | $1.27B | $1.14B | $979.7M | $1.09B | $1.05B | $967.1M | $819.9M | $943.6M | $858.9M |
| Gross margin | 93.7% | 91.8% | 92.0% | 92.8% | 93.5% | 93.0% | 92.5% | 92.4% | 92.7% | 93.1% | 93.1% | 93.5% |
| Operating income | $697.9M | $301.1M | $335.9M | $443.5M | $530.3M | $205.2M | $301.5M | $146.1M | -$478.1M | $91.9M | $187.3M | $214.7M |
| Net income | $585.6M | $303.3M | $299.3M | $424.2M | $405.0M | $158.2M | $201.2M | $106.5M | -$444.6M | $169.5M | $201.1M | $171.3M |
| Net margin | 35.0% | 23.8% | 19.9% | 31.1% | 33.3% | 15.0% | 17.1% | 9.4% | −42.6% | 19.2% | 19.8% | 18.6% |
| Diluted EPS | $2.81 | $1.47 | $1.46 | $2.11 | $2.04 | $0.80 | $1.00 | $0.54 | $-2.04 | $0.75 | $0.89 | $0.76 |
| EBITDA | $724.4M | $348.1M | $414.0M | $455.3M | $311.0M | $227.5M | $300.4M | $192.0M | -$455.2M | $113.8M | $224.1M | $235.7M |
| Operating cash flow | $507.7M | $369.4M | $543.3M | $559.4M | $44.7M | $266.1M | $381.2M | $310.9M | -$575.6M | $218.8M | $147.7M | $162.4M |
| Free cash flow | $495.2M | $359.2M | $521.4M | $544.6M | $25.7M | $262.9M | $363.8M | $305.7M | -$629.7M | $209.3M | $145.5M | $151.4M |
| Diluted shares | 208.2M | 206.8M | 204.4M | 201.4M | 198.7M | 198.2M | 200.9M | 195.8M | 218.2M | 227.2M | 226.3M | 226.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.98B | $3.46B | $3.10B | $2.46B | $1.95B | $1.94B |
| Short-term investments | $553.4M | $554.7M | $482.8M | $474.8M | $466.8M | $466.9M |
| Total debt | $32.7M | $33.8M | $34.7M | $35.4M | $36.2M | $37.1M |
| Total assets | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B |
| Total liabilities | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B |
| Shareholders' equity | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology